PDPN and neoplasm: To perform clinical trials using spontaneously occurring canine tumor models, we developed a cancer-specific anti-canine PDPN (dPDPN) monoclonal antibody (mAb), PMab-38, which recognizes only dPDPN expression in canine tumor tissues without recognizing normal canine tissues [16].